Changes in bone biochemical markers after high-dose cerivastatin treatment in a woman with osteogenesis imperfecta

Journal of Bone and Mineral Metabolism

Volumn 19, Issue 6, 2001, Pages 382-384

  Sugiyama, Toshihiro ^a   Kawai, Shinya ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metabolism; Bone specific alkaline phosphatase; Cerivastatin; HMG CoA reductase inhibitor; Osteogenesis imperfecta

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCITRIOL; CALCIUM; CERIVASTATIN; CHOLESTEROL; DEOXYPYRIDINOLINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE METABOLISM; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; OSSIFICATION; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOGENESIS IMPERFECTA; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDINES; TIME FACTORS;

EID: 0034765171     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007740170009     Document Type: Article

References (16)

1. Recent progress in diagnosis and treatment of osteogenesis imperfecta
2. A fourier transform infrared spectroscopic and solid-state NMR study of bone mineral in osteogenesis imperfecta
3. Are drugs helpful in adults with osteogenesis imperfecta?
4. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
5. Severe osteogenesis imperfecta: New therapeutic options?
6. Stimulation of bone formation in vitro and in rodents by statins
7. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
8. Cerivastatin increases BMP-2 expression in vivo and bone formation in concentrations of two orders of magnitude lower than other statins
9. Cerivastatin increases cortical bone formation in OVX rats
10. Efficacy and safety of cerivastatin 0.8mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
11. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
12. HMG-CoA reductase inhibitors and the risk of fractures
13. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
14. Does statin use reduce risk of fracture in post-menopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS)
15. Use of statins and risk of fractures
16. Dermal application of lovasatin to rats causes greater increses in bone formation and plasma concentrations than when administered by oral gavage